Molecular regulation of TLR2-mediated autoimmune inflammation
TLR2介导的自身免疫炎症的分子调控
基本信息
- 批准号:10507768
- 负责人:
- 金额:$ 39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-11-15 至 2024-10-31
- 项目状态:已结题
- 来源:
- 关键词:AmplifiersAntigensAutoantigensAutoimmuneAutoimmune DiseasesAutoimmunityAutomobile DrivingBindingCD4 Positive T LymphocytesCHD7 geneCell physiologyCellsCentral Nervous SystemChromatinChronicDataDevelopmentDiseaseDistalElementsEpigenetic ProcessEventExperimental Autoimmune EncephalomyelitisFailureGene AmplificationGenerationsGenesGeneticGenetic ProgrammingGenetic TranscriptionGoalsIn VitroInflammationInflammatoryInflammatory ResponseLaboratoriesLigandsLymphocyte ActivationLymphocyte FunctionMediatingMethylationModelingMolecularMultiple SclerosisMusMyelinPathogenesisPathogenicityPathway interactionsPublishingRUNX3 geneReceptor ActivationRegulationRegulatory ElementRepressionResearchRoleSeminalSignal TransductionT-Cell ActivationT-LymphocyteTLR2 geneTestingTh1 CellsTherapeutic InterventionTissuesTranscriptional RegulationWorkantagonistautoimmune inflammationautoreactivitycentral nervous system demyelinating disorderchromatin modificationcytokinedesignin vivomouse modelnovelpermissivenesspreventprogramsreceptorresponsescaffoldsuccesstranscription factorvirtual
项目摘要
SUMMARY
The mechanisms governing CD4+ T cell activation and function in autoimmune disease remain insufficiently
understood even though autoreactive CD4+ T cells are central orchestrators for the initiation and progression of virtually
all autoimmune diseases. Multiple sclerosis (MS), a demyelinating disease of the central nervous system (CNS), is a well
characterized example of how the failure to control autoreactive CD4+ T cells can lead to devastating inflammation and
tissue damage. Encephalitogenic CD4+ T helper (Th) cells, especially Th17 and Th1 cells, promote CNS inflammation by
responding to self-antigens both in MS and the murine MS model, experimental autoimmune encephalomyelitis (EAE).
Our seminal work has identified an innate-like receptor with critical roles in driving the pathogenicity of encephalitogenic
Th17 cells in vivo. Since, we have further identified key transcriptional and epigenetic mechanisms associated with this
pathway, indicating that innate-like signaling drives signature programming events that render Th17 cells altogether more
pathogenic for autoimmune inflammation. Our preliminary work presented herein demonstrates that activation of this
pathway amplifies gene-promoting chromatin modifications at Th17-related loci, likely resulting in increased access for
pro-inflammatory transcription factors as well as the binding of a novel chromatin regulatory factor. This chromatin
regulator was recently characterized by our laboratory and we demonstrate its essentiality in mediating Th17 cell-
dependent autoimmune inflammation. Finally, our data demonstrates that endogenous ligands are potent amplifiers of this
pathway as well as encephalitogenicity in Th17 cells. Taken together, these novel results suggest that autoimmune
disorders may be treated through targeting the downstream effects of this pathway to inhibit Th17 cells. Therefore, the
goal of these studies is to characterize the mechanisms responsible for the increased inflammatory potential that we have
firmly established in these Th17 cells. Transcriptional, epigenetic, and functional analyses will be performed to tease out
the contributions of the novel regulatory factors identified by our preliminary work. Consequently, our project is designed
to test our central hypothesis through two interlinked specific aims.
总结
自身免疫性疾病中CD4+ T细胞活化和功能的调控机制仍不充分
尽管自身反应性CD4+ T细胞是启动和发展几乎所有免疫缺陷的核心,
所有自身免疫性疾病。多发性硬化症(MS)是中枢神经系统(CNS)的脱髓鞘疾病,
这是一个典型的例子,说明无法控制自身反应性CD4+ T细胞如何导致破坏性炎症,
组织损伤致脑性CD4+辅助性T(Th)细胞,特别是Th17和Th1细胞,通过以下方式促进CNS炎症:
在MS和鼠MS模型中,实验性自身免疫性脑脊髓炎(EAE)对自身抗原应答。
我们的开创性工作已经确定了一个先天性受体,在驱动致脑炎性疾病的致病性中起关键作用。
体内Th17细胞。从那时起,我们进一步确定了与此相关的关键转录和表观遗传机制。
这表明,先天性信号转导驱动签名编程事件,使Th17细胞更
自身免疫性炎症的病原体。我们在此提出的初步工作表明,激活这种
途径放大了Th17相关基因座的基因促进染色质修饰,可能导致Th17相关基因的获得增加。
促炎转录因子以及新的染色质调节因子的结合。这个染色质
调节因子最近由我们的实验室表征,我们证明了它在介导Th17细胞中的重要性,
依赖性自身免疫性炎症最后,我们的数据表明,内源性配体是这一过程的有效放大器。
途径以及Th17细胞中的致脑炎性。总之,这些新的结果表明,
可以通过靶向该途径的下游效应以抑制Th17细胞来治疗疾病。因此
这些研究的目的是描述导致我们所具有的增加的炎症潜能的机制。
在Th17细胞中牢固地建立。将进行转录、表观遗传和功能分析,
我们的初步工作确定的新型调节因素的贡献。因此,我们的项目设计
通过两个相互关联的具体目标来检验我们的中心假设。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Toll-like receptor 2 induces pathogenicity in Th17 cells and reveals a role for IPCEF in regulating Th17 cell migration.
- DOI:10.1016/j.celrep.2021.109303
- 发表时间:2021-06-29
- 期刊:
- 影响因子:8.8
- 作者:Marks KE;Flaherty S;Patterson KM;Stratton M;Martinez GJ;Reynolds JM
- 通讯作者:Reynolds JM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Michael Reynolds其他文献
Joseph Michael Reynolds的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Michael Reynolds', 18)}}的其他基金
Molecular regulation of TLR2-mediated autoimmune inflammation
TLR2介导的自身免疫炎症的分子调控
- 批准号:
10054100 - 财政年份:2018
- 资助金额:
$ 39万 - 项目类别:
Molecular regulation of TLR2-mediated autoimmune inflammation
TLR2介导的自身免疫炎症的分子调控
- 批准号:
10290308 - 财政年份:2018
- 资助金额:
$ 39万 - 项目类别:
Critical roles of endogenous TLR signaling in driving Th17 effector responses
内源性 TLR 信号在驱动 Th17 效应反应中的关键作用
- 批准号:
8487096 - 财政年份:2013
- 资助金额:
$ 39万 - 项目类别:
Critical roles of endogenous TLR signaling in driving Th17 effector responses
内源性 TLR 信号在驱动 Th17 效应反应中的关键作用
- 批准号:
8707966 - 财政年份:2013
- 资助金额:
$ 39万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 39万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别: